Edition:
India

Moleculin Announces Agreement To Produce WP1122 For Expanded Development Of Potential Covid-19 And Oncology Drug Candidate


Wednesday, 15 Jul 2020 

July 15 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES AGREEMENT TO PRODUCE WP1122 FOR EXPANDED DEVELOPMENT OF POTENTIAL COVID-19 AND ONCOLOGY DRUG CANDIDATE.MOLECULIN BIOTECH INC - ENTERED INTO AN AGREEMENT WITH STERLING PHARMA USA LLC.MOLECULIN BIOTECH - EXPANDING PLANNED PRECLINICAL STUDIES FOR IND, INCLUDING TESTING MULTIPLE ANALOGS OF WP1122 AGAINST VARIOUS VIRUSES IN VITRO.MOLECULIN BIOTECH INC - PLANNED TESTS ARE INTENDED TO PROVIDE ADDITIONAL COMPARATIVE DATA OF WP1122 AND ITS CLOSE ANALOGS.MOLECULIN BIOTECH INC - BELIEVES MECHANISM OF ACTION OF 2-DG AND WP1122 IS VERY DIFFERENT FROM OTHER DRUGS BEING DEVELOPED FOR COVID-19.MOLECULIN BIOTECH INC - COMPANY WILL SEEK TO EVALUATE WP1122 IN AN ANIMAL MODEL FOR COVID-19 AS A PART OF ITS IND PREPARATION.MOLECULIN BIOTECH -BELIEVE CONVENTIONAL METHODS OF ANTIVIRAL TESTING MAY NOT BE IDEALLY SUITED TO TEST CLASS OF AGENTS REPRESENTED BY 2-DG & WP1122.